TY  - GEN
AU  - Liu,Pei Y
AU  - Sokolowski,Nicholas
AU  - Guo,Su T
AU  - Siddiqi,Faraz
AU  - Atmadibrata,Bernard
AU  - Telfer,Thomas J
AU  - Sun,Yuting
AU  - Zhang,Lihong
AU  - Yu,Denise
AU  - Mccarroll,Joshua
AU  - Liu,Bing
AU  - Yang,Rui H
AU  - Guo,Xiang Y
AU  - Tee,Andrew E
AU  - Itoh,Ken
AU  - Wang,Jenny
AU  - Kavallaris,Maria
AU  - Haber,Michelle
AU  - Norris,Murray D
AU  - Cheung,Belamy B
AU  - Byrne,Jennifer A
AU  - Ziegler,David S
AU  - Marshall,Glenn M
AU  - Dinger,Marcel E
AU  - Codd,Rachel
AU  - Zhang,Xu D
AU  - Liu,Tao
TI  - The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs
SN  - 1949-2553
PY  - 2018///0212
KW  - Animals
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Azepines
KW  - Cell Cycle Proteins
KW  - Cell Line, Tumor
KW  - Cell Proliferation
KW  - drug effects
KW  - Cell Survival
KW  - Drug Synergism
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Mice
KW  - NF-E2-Related Factor 2
KW  - metabolism
KW  - Naphthoquinones
KW  - Neuroblastoma
KW  - drug therapy
KW  - Nuclear Proteins
KW  - Protein Domains
KW  - RNA-Binding Proteins
KW  - Small Molecule Libraries
KW  - Transcription Factors
KW  - Triazoles
KW  - Tubulin Modulators
KW  - Vincristine
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.18632/oncotarget.12640
ER  -